Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

Part of paid clinical trials in Lexington, Kentucky.

Sponsor
Rachel Miller
Study ID
NCT03089554
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Therapeutic Intervention — DRUG
    Therapeutic Intervention

Study Details

This is a substudy (Part 2) of a larger two-part clinical trial including both observational and therapeutic (interventional) cohorts to assess the progression free survival ratio of patients treated with a targeted therapy based on genomic analysis results and recommendation by the Markey Cancer Center Molecular Tumor Board (MCC MTB).

Key Dates

Start date
Apr 11, 2017
Status verified
May 2026
Primary completion
Apr 30, 2027
Completion
Apr 30, 2027

Study Design

Enrollment
93 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Therapeutic Intervention
    Therapeutic Intervention

Primary Outcome Measure

Progression Free Survival [ Time Frame: 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Markey Cancer Center, University of KentuckyLexingtonKentucky40536
Rachel Miller, MD
[email protected]
859-323-2196
Rachel Miller, M.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Lexington, KY

By research site
Markey Cancer Center, University of Kentucky· Lexington, KY

Related Studies